Milestone Pharmaceuticals Inc — 貸借対照表 (NASDAQ:MIST) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

総資産 149.97 M119.85 M74.48 M75.23 M75.5 M113.56 M 負債合計 6.86 M7.25 M8.13 M58.45 M62.35 M71.79 M 純資産合計 143.12 M112.6 M66.35 M16.77 M13.15 M41.77 M 負債および純資産合計 149.97 M119.85 M74.48 M75.23 M75.5 M113.56 M 有利子負債合計 ———51.77 M54.8 M58.38 M 純負債 ———-14.22 M-14.9 M-47.62 M

ニュース

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Stock: Downgrading To Sell As CARDAMYST Faces A Tough Reality (NASDAQ:MIST)

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

アプターの点鼻スプレーシステム、新承認のPSVT治療薬の投与に採用

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)

TD Cowen、FDA承認を受けてマイルストーン・ファーマシューティカルズの格付けを「買い」に引き上げ

Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment - Slideshow (NASDAQ:MIST) 2025-12-15